Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals has reported Operating Expenses for 10 years, with the latest figure at $195.3 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 12.75% year-over-year to $195.3 million in Q2 2026; TTM through Jun 2026 was $762.8 million, a 9.67% increase from a year earlier, with the FY2025 full-year figure at $717.2 million, up 7.13% from the prior year.
• Operating Expenses was $195.3 million for Q2 2026 at Amneal Pharmaceuticals, up from $182.4 million in the prior quarter.
• The five-year high for Operating Expenses was $201.3 million in Q3 2025, with the low at $141.3 million in Q1 2023.
• Average Operating Expenses over 5 years is $164.3 million, with a median of $155.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses declined 7.82% in 2022, then advanced 18.2% in 2024.
• Over 5 years, Operating Expenses stood at $144.2 million in 2022, then gained by 7.65% to $155.2 million in 2023, then rose by 18.2% to $183.4 million in 2024, then gained by 0.16% to $183.7 million in 2025, then rose by 6.31% to $195.3 million in 2026.
• The last three Operating Expenses figures came in at $195.3 million (Q2 2026), $182.4 million (Q1 2026), and $183.7 million (Q4 2025), per Business Quant data.